Improving clinical pathways for abdominal aortic aneurysm through incorporating biomarkers (Old ID 27513)
Role
Chief Investigator
Description
20 million people worldwide have weakening of their main abdominal artery (abdominal aortic aneurysm; AAA) and are at high risk of both major adverse cardiovascular events (MACE) and AAA related events (AAA repair and rupture-related death). Most AAAs are identified at a small size when their risk of rupture is low. Management of small AAA focuses on repeat aortic imaging every 6 months to identify when the threshold diameter (50mm in women and 55mm in men) is reached for elective surgical AAA repair. Most small AAAs continue to grow in size and eventually undergo repair. No drugs have been shown to limit AAA growth and the clinical pathway focuses on identifying those needing surgery rather than medical management. There are no established means to individualise care. Our interviews with patients and health professionals indicate that the number one deficiency in current AAA management is the lack of individualising medical management to reduce the high incidence of MACE and AAA related events. Our international AAA alliance is uniquely placed due to our resources (biobank-registry) and IP (bioinformatics, clinical, engineering software, genomics, biomarkers, machine learning and pathogenesis) to addresses this unmet clinical need.
Date
01 Jun 2023 - 31 May 2026
Project Type
GRANT
Keywords
Prevention;Complications;Peripheral artery disease;Risk Factors
Funding Body
ACN 010 494 836 PTY LTD, Commonwealth Department of Health
Amount
1007897.6
Project Team
Catherine Rush;Joseph Moxon;Aaron Drovandi;Jenna Pinchbeck;Matt Field;Rebecca Evans